CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS

被引：0
|
作者：
Hiken, Eliah J. [1 ]
Poweleit, Ethan A. [1 ]
Keane, Corey [1 ]
Desta, Zeruesenay [1 ]
Strawn, Jeffrey R. [1 ]
Ramsey, Laura B.
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2023年 / 62卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2023.09.140
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
2.53
引用
收藏
页码：S197 / S197
页数：1
相关论文
共 50 条
  • [31] Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects
    Zhang, Xiaodan
    Liu, Chengquan
    Zhou, Shuang
    Xie, Ran
    He, Xu
    Wang, Zhiqi
    Yi, Honghong
    Shu, You
    Wang, Zining
    Hu, Kun
    Ma, Lingyue
    Cui, Yimin
    Zhao, Xia
    Xiang, Jin
    PHARMACOGENOMICS, 2021, 22 (04) : 213 - 223
  • [32] Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Kirchheiner, J
    Henckel, HB
    Franke, L
    Meineke, I
    Tzvetkov, M
    Uebelhack, R
    Roots, I
    Brockmöller, J
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (08): : 579 - 587
  • [33] A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype
    Chida, M
    Yokoi, T
    Nemoto, N
    Inaba, M
    Kinoshita, M
    Kamataki, T
    PHARMACOGENETICS, 1999, 9 (03): : 287 - 293
  • [34] Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype
    Corruble, E.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (05): : 727 - 728
  • [35] Impact of the CYP2D6 utrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers
    Kirchheiner, J
    Henckel, HB
    Meineke, I
    Roots, I
    Brockmöller, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (06) : 647 - 652
  • [36] A NOVEL CYP2D6 ALLELE WITH AN ABOLISHED SPLICE RECOGNITION SITE ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE
    MAREZ, D
    SABBAGH, N
    LEGRAND, M
    LOGUIDICE, JM
    BOONE, P
    BROLY, F
    PHARMACOGENETICS, 1995, 5 (05): : 305 - 311
  • [37] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation
    de Leon, J
    Susce, MT
    Pan, RM
    Fairchild, M
    Koch, WH
    Wedlund, PJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) : 15 - 27
  • [38] Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype
    Gaedigk, A.
    Eklund, J. D.
    Pearce, R. E.
    Leeder, J. S.
    Alander, S. W.
    Phillips, M. S.
    Bradford, L. D.
    Kennedy, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (06) : 817 - 820
  • [39] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
    Martinez de Duenas, Eduardo
    Ochoa Aranda, Enrique
    Blancas Lopez-Barajas, Isabel
    Ferrer Magdalena, Teresa
    Bandres Moya, Fernando
    Chicharro Garcia, Luis Miguel
    Gomez Capilla, Jose A.
    Zafra Ceres, Mercedes
    de Haro, Tomas
    Romero Llorens, Regina
    Ferrer Albiach, Carlos
    Ferriols Lisart, Rafael
    Chover Lara, Dolores
    Lopez Rodriguez, Angela
    Munarriz Ferrandis, Javier
    Olmos Anton, Santiago
    BREAST, 2014, 23 (04): : 400 - 406
  • [40] Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns
    Wendt, Frank R.
    Novroski, Nicole M. M.
    Rahikainen, Anna-Liina
    Sajantila, Antti
    Budowle, Bruce
    AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY, 2019, 40 (01): : 8 - 18
12345